<DOC>
	<DOCNO>NCT00730535</DOCNO>
	<brief_summary>This Phase IV , prospective , randomize , multi-center study find risk factor OAB symptom relapse patient show therapeutic benefit 1 , 3 , 6 month treatment Tolterodine SR discontinue antimuscarinics 3 month . Patients OAB symptoms 6 6 month show successful treatment response 1 month treatment Tolterodine SR 4mg enrol randomize 1 , 3 6 month treatment group . After completion treatment , subject evaluate change OAB symptom retreatment rate assess .</brief_summary>
	<brief_title>Exploring Predictors Symptoms Relapse After Discontinuation Treatment Overactive Bladder ( OAB ) Patients</brief_title>
	<detailed_description>Primary Objective : - To investigate risk factor OAB symptom relapse retreatment patient show therapeutic benefit 1 , 3 6 month treatment Tolterodine SR discontinue antimuscarinics 3 month . Secondary Objective : - To investigate change patient perception quality life antimuscarinic discontinuation - To find rate patient OAB symptom relapse . - To find risk factor patient want retreatment . - To find rate patient want retreatment .</detailed_description>
	<mesh_term>Recurrence</mesh_term>
	<mesh_term>Urinary Bladder , Overactive</mesh_term>
	<mesh_term>Tolterodine Tartrate</mesh_term>
	<criteria>1 . Female age 18≤and ≤80 year 2 . Symptoms urinary urgency ( define level 3 5 5 point Urinary Sensation Scale ) 2 time per day 3 . Symptoms urinary frequency ( ≥ 8 micturition per 24 hour ) verify baseline micturition diary . 4 . Symptoms overactive bladder , include urinary urge incontinence , urgency and/or frequency ≥6 month . 5 . Ability willingness correctly complete micturition diary questionnaire 6 . Capable understanding sign informed consent form full discussion research nature treatment risk benefit 1 . Clinical significant stress incontinence determine investigator confirm female patient cough provocation test 2 . An average volume void &gt; 200 ml per micturition verify baseline micturition diary 3 . Total daily urine volume &gt; 3000 ml verify baseline micturition diary 4 . Significant hepatic renal disease , define twice upper limit reference range serum concentration aspartate aminotransferase ( AST [ SGOT ] ) , alanine aminotransferase ( ALT [ SGPT ] ) , alkaline phosphatase creatinine 5 . Any condition contraindication anticholinergic treatment , include uncontrolled narrowangled glaucoma , urinary retention gastric retention 6 . Symptomatic acute urinary tract infection ( UTI ) runin period 7 . Recurrent UTIs define treat symptomatic UTIs &gt; 4 time last year 8 . Diagnosed suspected interstitial cystitis 9 . Uninvestigated hematuria hematuria secondary malignant disease . 10 . Clinically significant bladder outlet obstruction define clinical symptom investigator 's opinion accord local standard care 11 . Patients mark cystocele clinically significant pelvic prolapse . 12 . On unstable dosage drug anticholinergic side effect , expect start treatment study 13 . Receipt electrostimulation bladder training within 14 day start tolterodine SR , expect start treatment study 14 . Use drug treatment overactive bladder ( e.g . anticholinergic except tolterodine ) within 14 day start tolterodine SR , expect start treatment study 15 . An indwelling catheter practice intermittent selfcatheterization 16 . Use investigational drug within 2 month precede start study 17 . Patients chronic constipation history severe constipation 18 . Pregnant nursing woman 19 . Sexually active female childbearing potential use reliable contraception least 1 month prior study start agree use method entire study period least 1 month thereafter . Reliable contraceptive method define intrauterine device ( IUDs ) , combination type contraceptive pill , hormonal implant , double barrier method , injectable contraceptive surgical procedure ( tubal ligation vasectomy ) . 20 . Patients bladder cancer 21 . Treatment potent CYP3A4 inhibitor , cyclosporine , vinblastine , macrolide antibiotic ( e.g . erythromycin , clarithromycin , azithromycin ) antifungal agent ( e.g . ketoconazole , itraconazole , micronazole ) . 22 . Any condition , opinion investigator , make patient unsuitable inclusion</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2011</verification_date>
	<keyword>Overactive bladder , Tolterodine , Symptoms Relapse , Predictor</keyword>
</DOC>